Insider Buying: Clarity Pharmaceuticals Ltd (ASX:CU6) Insider Acquires 905,625 Shares of Stock

Clarity Pharmaceuticals Ltd (ASX:CU6) insider Colin Biggin acquired 905,625 shares of the business’s stock in a transaction dated Wednesday, August 7th. The shares were acquired at an average price of A$0.67 ($0.44) per share, for a total transaction of A$604,957.50 ($397,998.36).

Colin Biggin also recently made the following trade(s):

• On Thursday, August 1st, Colin Biggin bought 542,835 shares of Clarity Pharmaceuticals stock. The shares were bought at an average price of A$0.67 ($0.44) per share, for a total transaction of A$363,156.62 ($238,918.83).

Clarity Pharmaceuticals Price Performance

About Clarity Pharmaceuticals

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2.